PHARMA DEALS DURING DECEMBER 2014
(Part 2 out of 2)
by Medius Associates
This table lists all the major pharma collaborations, acquisitions and mergers agreed during December 2014
Licensor acquired / licensee acquirer
|
Product / technology
|
Deal type
|
Headline ($m)
|
| Cubist / Merck & Co | Portfolio of marketed and late stage antibiotics | Company acquisition | 9,500 |
| Avanir Pharmaceuticals / Otsuka Pharmaceutical | Portfolio of CNS products, inc Nuedexta marketed for pseudobulbar affect | Company acquisition | 3,500 |
| *Astellas/ J&J | ASP015K, an oral JAK inhibitor for RA (p3) | Exercise of opt-out/ termination | **945 |
| Macrogenics / J&J | MGD011, bispecific DART antibody for B-cell haematological malignancies (preclinical) | Licence | 700 |
| Cytokinetics / Astellas Pharma | CK-2127107, fast skeletal troponin activator, in Spinal Muscular Atrophy and other neuromuscular indications (p1) | Expansion of collaboration/ amended agreement | 675 |
| Halozyme Therapeutics / J&J | ENHANZE rHuPH20 delivery technology for up to 5 targets | Collaboration, licence | 581 |
| Opko Health / Pfizer | Long-acting hGH-CTP for growth hormone deficiency in adults and children (p3) | Licence | 570 |
| Adocia / Eli Lilly | BioChaperone Lispro (ultra-rapid insulin) based on BioChaperone technology (p1b) | Licence, collaboration | 570 |
| Dutalys / Roche | DutaMab technology for development of fully human, bispecific antibodies | Company acquisition | 489 |
| PneumRx / BTG | Portfolio of medical devices for interventional pulmonology inc RePneu Coil | Company acquisition | 475 |
| ***GeNeuro / Servier | GNbAC1, mab to inhibit progression of MS without suppressing the immune system (p2) | Collaboration, option to license + take equity stake | 455 |
| Zosano Pharma / Eli Lilly | ZP-PTH (parathyroid hormone 1-34) delivered via microneedle patch system (p2) | Licence | 440 |
| OncoEthix / Merck & Co | Lead product oral BET inhibitor, OTX015 for oncology indications (p1b) | Company acquisition | 375 |
| Evotec / Sanofi | R&D alliance to progress Sanofi discovery phase compounds to preclinical stage (inc Sanofi discovery facility with 200 scientists) | Exclusive negotiations to create 5-year strategic alliance | 310 |
| Array BioPharma / Oncothyreon | ONT-380 (ARRY-380), oral, reversible and selective small molecule HER2 inhibitor (p1) | Licence - amended agreement | †300 |
| Spark Therapeutics / Pfizer | Multiple haemophilia B gene therapy products (preclinical) | Gene therapy collaboration | 280 |
| Xencor / Novo Nordisk | XmAb technologies, inc bispecific and immune inhibitor technologies, for undisclosed target | Collaboration, licence | 175 |
| Phylogica / Genentech | Phylomer drug discovery platform for novel antibiotics | Research & licensing agreement | 142.5 |
| Boston Heart Diagnostics / Eurofins Scientific | Diagnostics tests for chronic conditions including cardiovascular diseases and diabetes | Company acquisition | 140 |
| Sevion Therapeutics / J&J | Spatially addressed antibody discovery platform | Research collaboration, options to license | 125 |
| ††Ariad Pharmaceuticals / Otsuka Pharmaceutical | Iclusig (ponatinib), inhibitor of BCR-ABL, for resistant and intolerant CML and Ph+ALL (JP NDA) | Co-development and commercialisation agreement | 77.5 |
All deals global
unless otherwise stated:
* ex Japan
** original deal
headline value
***ex US, JP
† If Oncothyreon
is acquired with 3 years of effective date, Array eligible for up to $280m
milestones
†† JP + 9 other
Asian countries (CML, chronic myeloid leukaemia ; Ph+ALL,
Philadelphia-chromosome positive acute lymphoblastic leukaemia)
Fuente: PMLiVE
Consultas al mail: msg.latam@gmail.com
Fuente: PMLiVE
Haciendo click en cada uno de los links siguientes,
accederán a los Contenidos de nuestros
TALLERES DE CAPACITACIÓN IN COMPANY A MEDIDA:
(translator on page)
¿Cómo INCORPORAR y APLICAR Modelos de
PENSAMIENTO ESTRATÉGICO?
(aplicado al Sector Salud y Farma, con resolución de casos reales en tiempo real)
PENSAMIENTO ESTRATÉGICO?
(aplicado al Sector Salud y Farma, con resolución de casos reales en tiempo real)
http://msg-latam-meic.blogspot.com.ar/2014/06/capacitacion-in-company-programa_6246.html
¿Cómo GERENCIAR EFICAZMENTE a partir del
MANAGEMENT ESTRATÉGICO?
(aplicado al Sector Salud y Farma, con resolución de casos reales en tiempo real)
http://msg-latam-meic.blogspot.com.ar/2014/06/capacitacion-in-company-programa_3.html
¿Cómo GERENCIAR PROCESOS DE CAMBIO
y no sufrir en el intento?
(aplicado al Sector Salud y Farma, con resolución de casos reales en tiempo real)
http://msg-latam-meic.blogspot.com.ar/2014/06/capacitacion-in-company-programa.html
¿Cómo IMPLEMENTAR ESTRATEGIAS EFECTIVAS?
Recetas para Escenarios Turbulentos
(aplicado al Sector Salud y Farma, con resolución de casos reales en tiempo real)
http://msg-latam-meic.blogspot.com.ar/2014/06/capacitacion-in-company-taller-de.html
Consultas al mail: msg.latam@gmail.com
ó al TE: +5411-3532-0510
Miguel Angel Medina Casabella, MSM, MBA, SMHS .·.
CoFundador y Miembro del Consejo Directivo, GW Alumni Association, Capítulo Argentino, desde 2009
Representante de The George Washington University en Foros y Ferias de LatAm desde 2001
Representante de The George Washington University Medical Center para LatAm desde 1998
CEO, MANAGEMENT SOLUTIONS GROUP LatAm
TE Oficina: ( 0054) 11 - 3532 - 0510
TE Celular (local): ( 011 ) 15 - 4420 - 5103
TE Celular (Int´l): ( 0054) 911 - 4420 - 5103
Skype: medinacasabella
es una Consultora Interdisciplinaria cuya Misión es proveer
soluciones integrales, eficientes y operativas en todas las áreas vinculadas a:
Estrategias Multiculturales y Transculturales,
Management Estratégico,
Gestión del Cambio,
Marketing Estratégico,
Inversiones,
Gestión Educativa,
Capacitación
de Latino América (LatAm), para los Sectores:
a) Salud, Farma y Biotech,
b) Industria y Servicios,
c) Universidades y Centros de Capacitación,
d) Gobierno y ONGs.
No comments:
Post a Comment